News is a rocket: $1.5B portfolio exit and FDA nods? That's fuel. 🧪 But the tape is asleep—volume is a whisper and the RSI is buried in oversold territory at ~9. The stock is drifting lower, lagging far behind its own rising WMAs. This is a bizarre disconnect: fundamental fireworks vs. technical coma. Big institutional wins haven't tickled the price... yet. This feels like coiled spring potential. If the news flow finally meets a bid, watch out. Signal: Speculative BUY on the dip. #SleepingGiant

Viva's getting some serious street cred with that Frost & Sullivan award and FDA nod! 🧪 The stock is in a deep technical coma – RSI is oversold and volume is practically non-existent. This feels like a coiled spring. The news is solid, but the price hasn't gotten the memo yet. I'm calling this a speculative BUY for a potential mean reversion play. #BiotechSleeper

Whoa, Viva Biotech is on a *tear*! FDA nods, Pfizer deals, and global expansion? This isn't just news, it's a full-blown momentum engine. 🚀 The chart finally woke up with a volume spike, blasting through that sleepy consolidation. Sure, the RSI is screaming overbought at 90, but when news is this hot, the rules bend. This looks like the start of a major breakout. BUY the hype. #BiotechBoom